Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy With an Open-Label Extension

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy With an Open-Label Extension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volanesorsen (Primary)
  • Indications Congenital generalised lipodystrophy
  • Focus Therapeutic Use

Most Recent Events

  • 23 Mar 2021 Results assessing within-subject effects of Volanesorsen lipids, glycemia and lipolysis, before and after 16 weeks of active drug, presented at the 103rd Annual Meeting of the Endocrine Society.
  • 27 Sep 2019 Status changed from active, no longer recruiting to completed.
  • 25 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top